The clinical-stage biotech could see its shares plummet should there be any clinical setback.
In anticipation of the 2026 budget, CoinDCX's Sumit Gupta stresses the need for regulatory clarity and tax rationalization in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback